英飞凡®联合英卓凡®在华获批一线治疗晚期或不可切除的肝细胞癌(HCC)成人患者

美通社
Apr 27

英飞凡®亦获批单药一线治疗晚期或不可切除的肝细胞癌(HCC)成人患者。 此次获批是基于全球III期临床研究HIMALAYA及中国队列结果。结果表明STRIDE方案和英飞凡®单药相较于索拉非尼展现出良好的获益-风险特征。 上海2026年4月27日 /美通社/ -- 阿斯利康今日宣布,中国国家药品监督管理局已正式批准英飞凡®(英文商品名:Imfinzi®,中文通用名:度伐利尤单抗)联合英卓凡®(英文...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10